BridgeBio Pharma, Inc. (BBIO)
USD 38.57
(0.44%)
USD 38.57
(0.44%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -527.72 Million | -419.49 Million | -497.93 Million | -399.71 Million | -253.58 Million | -136.64 Million |
| Net Income | -653.25 Million | -484.65 Million | -586.45 Million | -505.48 Million | -288.58 Million | -169.45 Million |
| Depreciation & Amortization | 6.49 Million | 6.77 Million | 5.84 Million | 3.08 Million | 859 Thousand | 245 Thousand |
| Deferred income taxes | -18.05 Million | - | -30.93 Million | -1.86 Million | -859 Thousand | -14.89 Million |
| Stock-based compensation | 115.01 Million | 91.55 Million | 99.5 Million | 58.45 Million | 21.37 Million | 6.06 Million |
| Change in working capital | 5.05 Million | 28.07 Million | -4.39 Million | 14.93 Million | -10.91 Million | 22.49 Million |
| Other non-cash items | 23.32 Million | -61.25 Million | 18.49 Million | 31.15 Million | 24.53 Million | 18.89 Million |
| Investing Cash Flow | 54.03 Million | 453.14 Million | -200.82 Million | -52.99 Million | -217.25 Million | -21.03 Million |
| Investments in PPE | -1.3 Million | -6.32 Million | -48.24 Million | -7.51 Million | -5.13 Million | -18.17 Million |
| Acquisitions | - | 120 Million | -35 Million | 21.24 Million | -5.49 Million | -2.85 Million |
| Investment purchases | -137.26 Million | -193.05 Million | -643.27 Million | -287.85 Million | -212.89 Million | - |
| Sales/Maturities of investments | 193.1 Million | 532.52 Million | 477.04 Million | 242.23 Million | 5.49 Million | - |
| Other Investing Activities | -503 Thousand | 120 Million | 48.65 Million | -21.09 Million | 784 Thousand | -2.85 Million |
| Financing Cash Flow | 451.53 Million | -13.13 Million | 736.44 Million | 447.18 Million | 398.79 Million | 501.54 Million |
| Debt repayment | - | -20.48 Million | -124.11 Million | -536.96 Million | -175.78 Million | -1.09 Million |
| Dividends payments | - | - | - | - | -997 Thousand | - |
| Common Stock Repurchased | -6.88 Million | -1.56 Million | -204.74 Million | -75.71 Million | 175.78 Million | - |
| Common Stock Issuance | 459.21 Million | 4.85 Million | 3.82 Million | 1.2 Million | 366.23 Million | 95.53 Million |
| Other Financing Activities | 458.41 Million | 4.06 Million | 1.06 Billion | 1.59 Billion | 33.55 Million | 407.1 Million |
| Accounts receivables | 15.32 Million | 15.16 Million | -19.74 Million | 2.84 Million | -2.84 Million | - |
| Accounts payables | 2.78 Million | -349 Thousand | 2.83 Million | -735 Thousand | -4.65 Million | 16.7 Million |
| Inventory | -15.32 Million | -15.16 Million | 19.74 Million | -2.84 Million | 2.84 Million | - |
| Other working capital | 2.27 Million | 28.42 Million | -7.22 Million | 15.66 Million | -6.25 Million | 5.79 Million |
| Cash at beginning of period | 416.88 Million | 396.36 Million | 358.67 Million | 364.19 Million | 436.24 Million | 92.37 Million |
| Cash at end of period | 394.73 Million | 416.88 Million | 396.36 Million | 358.67 Million | 364.19 Million | 436.24 Million |
| Capital Expenditure | -1.3 Million | -6.32 Million | -48.24 Million | -7.51 Million | -5.13 Million | -18.17 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -22.15 Million | 20.51 Million | 37.68 Million | -5.51 Million | -72.04 Million | 343.86 Million |
| Free Cash Flow | -529.02 Million | -425.81 Million | -546.18 Million | -407.23 Million | -258.72 Million | -154.82 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -73.45 Million | -35.21 Million | -170.32 Million | -653.25 Million | -179.48 Million | -160.7 Million |
| Depreciation & Amortization | 1.57 Million | 1.59 Million | 1.58 Million | 6.49 Million | 1.63 Million | 1.63 Million |
| Deferred income taxes | - | - | -22.3 Million | -18.05 Million | 5.62 Million | -1.54 Million |
| Stock-based compensation | 21.45 Million | 17.05 Million | 37.02 Million | 108.71 Million | 22.6 Million | 27.17 Million |
| Change in working capital | 246.43 Million | -225.19 Million | 21.97 Million | 5.05 Million | 1.31 Million | 13.56 Million |
| Other non-cash items | -346.32 Million | 282.14 Million | 7.22 Million | 23.32 Million | 3.08 Million | 6.51 Million |
| Investing Cash Flow | 3.03 Million | 22.75 Million | -66 Thousand | 54.03 Million | 37.68 Million | 4.11 Million |
| Investments in PPE | -2.44 Million | -1.49 Million | -435 Thousand | -1.3 Million | -431 Thousand | -428 Thousand |
| Acquisitions | -98 Thousand | - | -369 Thousand | - | -38.11 Million | -4.54 Million |
| Investment purchases | -49.41 Million | -64.66 Million | -29.22 Million | -137.26 Million | -16.78 Million | -43.78 Million |
| Sales/Maturities of investments | 55 Million | 63.22 Million | 29.59 Million | 193.1 Million | 54.89 Million | 48.33 Million |
| Other Investing Activities | -98 Thousand | 25.68 Million | 369 Thousand | -503 Thousand | 38.11 Million | 4.54 Million |
| Financing Cash Flow | -5.72 Million | 279.54 Million | -4.52 Million | 451.53 Million | 307.04 Million | -1.23 Million |
| Debt repayment | -3.73 Million | -35.67 Million | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -1.74 Million | -2.93 Million | -2.55 Million | -6.88 Million | -2.61 Million | -1.2 Million |
| Common Stock Issuance | -254 Thousand | 318.15 Million | 333 Thousand | 459.21 Million | 312.71 Million | 1.15 Million |
| Other Financing Activities | -3.73 Million | -12.25 Million | -1.96 Million | 458.41 Million | 309.65 Million | -28 Thousand |
| Accounts receivables | 234.83 Million | -233.74 Million | 3.41 Million | 15.32 Million | 3.44 Million | 2.14 Million |
| Accounts payables | 14.78 Million | -5.92 Million | 6.18 Million | 2.78 Million | 694 Thousand | -298 Thousand |
| Inventory | - | - | -3.41 Million | -15.32 Million | -3.44 Million | -2.14 Million |
| Other working capital | -3.18 Million | 14.47 Million | 15.79 Million | 2.27 Million | 617 Thousand | 13.86 Million |
| Cash at beginning of period | 475.35 Million | 392.58 Million | 524.14 Million | 416.88 Million | 324.64 Million | 435.1 Million |
| Cash at end of period | 547.36 Million | 475.35 Million | 394.73 Million | 394.73 Million | 524.14 Million | 324.64 Million |
| Capital Expenditure | -2.44 Million | -1.49 Million | -435 Thousand | -1.3 Million | -431 Thousand | -428 Thousand |
| Effect of forex changes on cash | - | - | -112.48 Million | - | - | 112.48 Million |
| Net cash flow / Change in cash | 72.01 Million | 82.76 Million | -129.4 Million | -22.15 Million | 199.49 Million | -110.46 Million |
| Free Cash Flow | 72.25 Million | -221.02 Million | -125.25 Million | -529.02 Million | -145.65 Million | -113.78 Million |
SECOY
OIII
4043
TCIIF
2901
BCO